The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice

• Published in: British journal of cancer Vol. 87; no. 4; pp. 465 - 470
• Main Authors: ZHAO, L, CHING, L.-M, KESTELL, P, BAGULEY, B. C
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 12.08.2002
• Subjects: Acids; Animals; Antigens, CD - genetics; Antineoplastic agents; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Cancer research; Chemotherapy; Clinical trials; Colonic Neoplasms - drug therapy; Colonic Neoplasms - metabolism; Colonic Neoplasms - pathology; Dose-Response Relationship, Drug; Drug dosages; Experimental Therapeutics; Laboratories; Medical research; Medical sciences; Mice; Mice, Inbred C57BL; Mice, Knockout; Necrosis; Neoplasm Transplantation; Pharmacokinetics; Pharmacology. Drug treatments; Receptors, Tumor Necrosis Factor - genetics; Receptors, Tumor Necrosis Factor, Type I; Serotonin; Serotonin - metabolism; Time Factors; Toxicity; Tumor Necrosis Factor-alpha - metabolism; Tumor Necrosis Factor-alpha - physiology; Tumor necrosis factor-TNF; Tumors; Xanthenes - pharmacokinetics; Xanthenes - therapeutic use; Xanthones; Antineoplastic agent; Carcinoma; Cytokine; Rodentia; Malignant tumor; Acetic acid derivative; Antivascular agent; Biological activity; Colonic disease; Signal transduction; Vertebrata; Chemotherapy; Mammalia; Treatment; Mouse; Tumor necrosis factor; Animal; Established cell line; Digestive diseases; Intestinal disease; Colon; Pharmacokinetics; Biological receptor

5,6-dimethylxanthenone-4-acetic acid, a novel antivascular anticancer drug, has completed Phase I clinical trial. Its actions in mice include tumour necrosis factor induction, serotonin release, tumour blood flow inhibition, and the induction of tumour haemorrhagic necrosis and regression. We have u...